DBV Technologies S.A. (DBVT) stock
DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF
$11.88+0.37 (+3.21%)
Close on Nov 11, 2026Market cap $746.99MP/E –Yield –
DBV Technologies r&d expenses
Research and development expenses are spending on new products and technology.
DBV Technologies's R&D Expenses for the twelve months ending Sep 30, 2026 was $144.48M, up 40.7% year over year. For fiscal 2025 it was $116.68M, up 30.6% from the year before. The highest annual figure on record is $116.68M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.68M | +30.6% |
| FY2024 | Dec 31, 2024 | $89.34M | +48.4% |
| FY2023 | Dec 31, 2023 | $60.22M | -20.3% |
| FY2022 | Dec 31, 2022 | $75.54M | +7.4% |
| FY2021 | Dec 31, 2021 | $70.34M | -30.8% |
| FY2020 | Dec 31, 2020 | $101.61M | -11.7% |
| FY2019 | Dec 31, 2019 | $115.10M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $47.00M | +64.3% |
| Q2 FY2026 | Jun 30, 2026 | $31.20M | -7.4% |
| Q1 FY2026 | Mar 31, 2026 | $33.40M | +55.3% |
| Q4 FY2025 | Dec 31, 2025 | $32.88M | +73.9% |
| Q3 FY2025 | Sep 30, 2025 | $28.60M | +20.9% |
| Q2 FY2025 | Jun 30, 2025 | $33.70M | +32.8% |
| Q1 FY2025 | Mar 31, 2025 | $21.50M | +0.5% |
| Q4 FY2024 | Dec 31, 2024 | $18.90M | +48.0% |
| Q3 FY2024 | Sep 30, 2024 | $23.66M | +71.5% |
| Q2 FY2024 | Jun 30, 2024 | $25.37M | +44.0% |
| Q1 FY2024 | Mar 31, 2024 | $21.40M | +33.5% |
| Q4 FY2023 | Dec 31, 2023 | $12.78M | -56.9% |
| Q3 FY2023 | Sep 30, 2023 | $13.80M | -8.6% |
| Q2 FY2023 | Jun 30, 2023 | $17.62M | -5.3% |
| Q1 FY2023 | Mar 31, 2023 | $16.04M | +31.2% |
| Q4 FY2022 | Dec 31, 2022 | $29.61M | +153.7% |
| Q3 FY2022 | Sep 30, 2022 | $15.10M | -7.5% |
| Q2 FY2022 | Jun 30, 2022 | $18.61M | -7.8% |
| Q1 FY2022 | Mar 31, 2022 | $12.22M | -44.9% |
| Q4 FY2021 | Dec 31, 2021 | $11.67M | -55.8% |
| Q3 FY2021 | Sep 30, 2021 | $16.32M | -36.6% |
| Q2 FY2021 | Jun 30, 2021 | $20.18M | -8.0% |
| Q1 FY2021 | Mar 31, 2021 | $22.16M | -19.5% |
| Q4 FY2020 | Dec 31, 2020 | $26.39M | – |
| Q3 FY2020 | Sep 30, 2020 | $25.75M | – |
| Q2 FY2020 | Jun 30, 2020 | $21.93M | – |
| Q1 FY2020 | Mar 31, 2020 | $27.53M | – |
See a number that looks wrong?